Petros Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joshua N. Silverman
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1185 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Dec 2, 2020
- CIK
- 0001815903
- Website
- petrospharma.com
- Similar Companies
- Business
- Petros Pharmaceuticals, Inc. (PTPI) is a pharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics for men's health conditions. The company offers Stendra (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction; and H100 (Tadalafil) tablets, a generic version of Cialis indicated for erectile dysfunction and benign prostatic hyperplasia; along with other men's health products including Padcev (enfortumab vedotin-ejfv) for advanced urothelial cancer and other oncology indications. Petros operates primarily in the United States, with headquarters in Uniondale, New York, and traces its roots to the acquisition of assets from Vivus, Inc. in 2022, building on technologies originally developed since the early 2010s. In recent developments, Petros Pharmaceuticals completed a significant reorganization in 2024, including a 1-for-22 reverse stock split and delisting from Nasdaq to focus on OTCQB trading under PTPI, aimed at streamlining operations and enhancing shareholder value. The company announced a strategic licensing agreement in mid-2025 with a leading generics manufacturer to expand distribution of H100 in key international markets, marking its entry into Europe and Asia-Pacific regions. Additionally, Petros launched a new patient assistance program in late 2024 for Stendra, improving accessibility amid competitive pressures in the ED market, and reported preliminary Q3 2025 earnings reflecting a 15% revenue uptick driven by H100 sales growth.
Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health